全文获取类型
收费全文 | 7152篇 |
免费 | 880篇 |
国内免费 | 175篇 |
专业分类
耳鼻咽喉 | 87篇 |
儿科学 | 256篇 |
妇产科学 | 63篇 |
基础医学 | 671篇 |
口腔科学 | 315篇 |
临床医学 | 1023篇 |
内科学 | 1419篇 |
皮肤病学 | 148篇 |
神经病学 | 964篇 |
特种医学 | 126篇 |
外科学 | 725篇 |
综合类 | 696篇 |
预防医学 | 766篇 |
眼科学 | 105篇 |
药学 | 318篇 |
1篇 | |
中国医学 | 46篇 |
肿瘤学 | 478篇 |
出版年
2023年 | 197篇 |
2022年 | 145篇 |
2021年 | 312篇 |
2020年 | 406篇 |
2019年 | 405篇 |
2018年 | 368篇 |
2017年 | 327篇 |
2016年 | 324篇 |
2015年 | 302篇 |
2014年 | 436篇 |
2013年 | 629篇 |
2012年 | 348篇 |
2011年 | 377篇 |
2010年 | 373篇 |
2009年 | 325篇 |
2008年 | 347篇 |
2007年 | 368篇 |
2006年 | 271篇 |
2005年 | 240篇 |
2004年 | 208篇 |
2003年 | 183篇 |
2002年 | 150篇 |
2001年 | 144篇 |
2000年 | 108篇 |
1999年 | 77篇 |
1998年 | 78篇 |
1997年 | 58篇 |
1996年 | 54篇 |
1995年 | 66篇 |
1994年 | 60篇 |
1993年 | 45篇 |
1992年 | 50篇 |
1991年 | 49篇 |
1990年 | 47篇 |
1989年 | 54篇 |
1988年 | 24篇 |
1987年 | 23篇 |
1986年 | 27篇 |
1985年 | 55篇 |
1984年 | 32篇 |
1983年 | 16篇 |
1982年 | 20篇 |
1981年 | 22篇 |
1980年 | 9篇 |
1979年 | 10篇 |
1978年 | 6篇 |
1977年 | 8篇 |
1976年 | 7篇 |
1975年 | 4篇 |
1973年 | 4篇 |
排序方式: 共有8207条查询结果,搜索用时 15 毫秒
1.
《The Journal for Nurse Practitioners》2022,18(2):164-167
Acute diarrhea is a condition of increased water stool content, stool volume, and number of bowel movements that lasts less than 14 days. Mild diarrhea is usually self-limiting; however, undertreated moderate to severe diarrhea may cause severe dehydration and lead to hypovolemic shock. In order to prevent severe dehydration and treat patients appropriately, it is crucial for health care providers to determine the right diagnosis of patients with acute diarrhea. This article focuses on pathophysiology, general patient presentation, diagnostic tests and differential diagnosis lists of acute diarrhea to discuss which diagnosis should be made based on patient presentation and objective data. 相似文献
2.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(4):908-917
Background and aimsReducing dietary cholesterol is generally acceptable for the prevention of cardiovascular disease (CVD). Eggs are nutrient-dense and common food items across the world, while rich in cholesterol. The potential effects of egg intake on cardiovascular health remain uncertainty and have been under debate in past decades.Methods and resultsA nationwide cohort of 20,688 participants aged 16–110 years without CVD at baseline were derived from the China Family Panel Studies. Egg consumption was assessed by a semi-quantitative food frequency questionnaire. We adopted stratified Cox proportional hazards model with random intercepts for provinces to evaluate associations of egg intake with CVD incidence. During a median follow-up of 6.0 years, we identified 2395 total CVD incidence and mean egg consumption was 3 times/week. Egg intakes were associated lower risks of CVD incidence in the multivariate-adjusted model. Compared with the non-consumers, the corresponding HRs (95% confidence interval) for total CVD events were 0.84 (0.74–0.94) for 1–2 times per week, 0.78 (0.69–0.88) for 3–6/week, and 0.83 (0.72–0.95) for ≥7/week. Similar relationships were found in hypertension. Approximately non-linear relationships were observed between egg consumption with total CVD and hypertension incidence, identifying the lowest risk in 3–6 times/week. Subgroup analyses estimated lower risks of total CVD and hypertension in females only, with significant effect modification by sex (P for interaction = 0.008 and 0.020).ConclusionEgg consumption may be associated with lower risks of CVD incidence among Chinese adults. Our findings could have implications in CVD prevention and might be considered in the development of dietary guidelines. 相似文献
3.
4.
Norito Katoh Hidehisa Saeki Yoko Kataoka Takafumi Etoh Satoshi Teramukai Hiroki Takagi Yuki Tajima Marius Ardeleanu Elena Rizova Kazuhiko Arima 《The Journal of dermatology》2019,46(4):290-300
Moderate to severe atopic dermatitis (AD) has a high disease burden and a significant effect on quality of life. Observational studies are necessary to determine the patient disease burden and long‐term disease control in the Japanese population. ADDRESS‐J is a non‐interventional, observational registry of adult Japanese patients with moderate to severe AD. Herein, we report baseline data from the ADDRESS‐J study describing disease characteristics and current treatment practices. At baseline, 300 adult AD patients with Investigator's Global Assessment (IGA) scores (range, 0–4) of 3 (moderate) or 4 (severe) whose treatments for AD were intensified, were assessed for clinical and patient‐reported outcomes and current AD treatments. The registry patients’ median age was 34.0 years; 60.7% were male and 71.7% had had AD for more than 20 years. At baseline, 220 study patients had an IGA score of 3 and 80 had an IGA score of 4. The median Eczema Area and Severity Index score was 21.7 (range, 0–72), the median body surface area involvement was 46.25%, and the median pruritus numerical rating scale score was 7.0 (range, 0–10); for each of these measures, higher scores represent greater severity. Most registry patients (86.7%) had recently used topical corticosteroids or topical calcineurin inhibitors as treatment for AD. This registry cohort represents a population of Japanese patients with moderate to severe AD and provides an important resource for characterizing the disease burden and evaluating the safety and effectiveness of various AD treatments. 相似文献
5.
6.
7.
8.
9.
《The Journal for Nurse Practitioners》2019,15(2):153-157.e1
Exposure to adverse childhood experiences (ACEs) contributes to 7 of the 10 leading causes of death in the United States as well as health risk behaviors, including substance abuse, physical inactivity, and high-risk sex behaviors. ACEs are traumatic childhood events that effect biopsychosocial health across the lifespan. It is vital for health care providers to view individuals from a trauma-informed perspective to guide best practice, but few are aware of ACEs, particularly those who treat adults. A review of the science of ACEs research, feasibility of screening for ACEs, and effective responses to trauma-impacted patients is presented in this report. 相似文献
10.
《Journal of the American Medical Directors Association》2020,21(2):172-180.e5
IntroductionOlder age is associated with multimorbidity and polypharmacy with high anticholinergic burden (ACB). High ACB is linked to adverse events such as poor physical functioning, dementia, cardiovascular disease, and falls. Interventions are needed to reduce this burden.Aims/ObjectivesThe aim was to systematically review the literature to identify and describe studies of clinical and cost-effectiveness of interventions designed to reduce ACB in adults (≥65 years) on polypharmacy regimes, compared with usual care. The objective was to answer the following questions: What are the contents of the interventions? Were these interventions clinically effective? Were these interventions cost effective?.Design, setting, and participantsSystematic review of interventions to reduce anticholinergic burden in adults aged 65 and older in any clinical setting.MethodsEligible papers reported primary or secondary research describing any type of intervention including systematic reviews, randomized controlled trials (RCTs), controlled clinical trials, or nonrandomized pre-post intervention studies (PPIs) published in English from January 2010 to February 2019. Databases searched included CINAHL, Ovid MEDLINE, EMBASE, and The Cochrane Central Register of Controlled Trials (CENTRAL).ResultsThe search yielded 5862 records. Eight studies (4 RCTs, 4 PPIs) conducted in hospital (4), community (2), nursing homes (1), and retirement villages (1) met the inclusion criteria. Pharmacists, either individually or as part of a team, provided the intervention in the majority of studies (6/8). Most (7/8) involved individual patient medication review followed by feedback to the prescriber. Two of the 4 RCTs and all non-RCTs reported a decrease in ACB following the intervention. No study reported cost outcome.Conclusions/ImplicationsPharmacists may be well placed to implement an ACB reduction intervention. This is the first systematic review of interventions to reduce ACB in older adults, and it highlights the need for development and testing of high-quality pragmatic clinical and cost-effectiveness trials in community and specific patient populations at high risk of harm from ACB.[PROSPERO registration: CRD42018089764]. 相似文献